

December 30, 2014

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (BC-118)	REFANEZUMAB
PRONUNCIATION	re" fe nez' ue mab
THERAPEUTIC CLAIM	Treatment for the recovery of motor function after stroke
CHEMICAL NAMES	

1. Immunoglobulin G1-kappa, anti-(human myelin-associated glycoprotein (Siglec-4a)); humanized mouse monoclonal antibody: γ 1 heavy chain (1-456) [human VH (IGHV7-4-1*02-(IGHD)-IGHJ4*01) (94%) [8.8.19] (1-126) -IGHG1*01 CH2[L⁵>A (244),G⁷>A (246)] (127-456)] (229-219')-disulfide with kappa light chain (1'-219') [human V-KAPPA (IGKV4-1*01-IGKJ2*01) (95%) [12.3.8] (1'-112') -IGKC*01 (113'-219')] dimer (235-235":238-238")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain

QQLVQSGSE	LKKPGASVKV	SCKASGYTFT	NYGMNWRQA	PGQGLEWMGW	50
INTYTGEPTY	ADDFTGRFVF	SLDTSVSTAY	LQISSLKAED	TAVYYCARNP	100
INYYGINYEG	YVMDYWGQGT	LVTVSSASTK	GPSVFPLAPS	SKSTSGGTAA	150
LGCLVKDYFP	EPVTVSWNSG	ALTSGVHTFP	AVLQSSGLYS	LSSVVTVPSS	200
SLGTQTYICN	VNHKPSNTKV	DKKVEPKSCD	KHTTCPPCPA	PELAGAPSVF	250
LFPPKPKDTL	MISRTPEVTC	VVVDVSHEDP	EVKFNWYVDG	VEVHNAKTKP	300
REEQYNSTYR	VVSVLTVLHQ	DWLNGKEYKC	KVSNKALPAP	IEKTIKAKG	350
QPREPQVYTL	PPSRDELTKN	QVSLTCLVKG	FYPSDIAVEW	ESNGQPENNY	400
KTTPPVLDSD	GSFFLYSKLT	VDKSRWQQGN	VFSCSVMHEA	LHNHYTQKSL	450
SLSPGK					456

Light chain

DIVMTQSPDS	LAVSLGERAT	INCKSSHSVL	YSSNQKNYLA	WYQQKPGQPP	50'
KLLIYWASTR	ESGVPDRFSG	SGSGTDFTLT	ISSLQAEDVA	VYYCHQYLSS	100'
LTFGQGTKLE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVVL	LNNFYPREAK	150'
VQWKVDNALQ	SGNSQESVTE	QDSKDYSTSL	SSTLTLSKAD	YEKHKVYACE	200'
VTHQGLSSPV	TKSFNRGEC				219'

Disulfide bridges

22-96	22"-96"	23'-94'	23"-94"	139'-199'	139"-199"	153-209	153"-209"
219'-229	219"-229"	235-235"	238-238"	270-330	270"-330"	376-434	376"-434"

Glycosylation sites (N)

Asn-306 Asn-306"

MOLECULAR FORMULA	C ₆₆₀₈ H ₁₀₁₅₆ N ₁₇₃₂ O ₂₀₆₄ S ₄₄ (peptide)
MOLECULAR WEIGHT	148.3 kDa (peptide)
TRADEMARK	None as yet
SPONSOR	GlaxoSmithKline
CODE DESIGNATIONS	GSK249320

REFANEZUMAB

Page 2 of 2

N14

157

CAS REGISTRY NUMBER 1233953-61-1

UNII 3ZZ278643V

WHO NUMBER 10174

gbk